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Edited by Varda RotterAbstract MDM2 is an E3 ubiquitin ligase which mediates
ubiquitylation and proteasome-dependent degradation of the p53
tumor suppressor protein. Phosphorylation of MDM2 by the
protein kinase AKT is thought to regulate MDM2 function in
response to survival signals, but there has been uncertainty
concerning the identity of the sites phosphorylated by AKT. In
the present study, we identify Ser-166, a site previously reported
as an AKT target, and Ser-188, a novel site which is the major
site of phosphorylation of MDM2 by AKT in vitro. Analysis of
MDM2 in cultured cells conﬁrms that Ser-166 and Ser-188 are
phosphorylated by AKT in a physiological context.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The p53 tumor suppressor protein is a highly labile tran-
scription factor which promotes growth arrest or apoptosis in
response to a host of environmental stresses [1–3]. p53 is
controlled mainly through its interaction with MDM2, an E3
ubiquitin ligase which mediates ubiquitylation and rapid pro-
teasome-dependent degradation of p53. Cellular stresses which
induce p53 disrupt the p53–MDM2 interaction, or inactivate
MDM2, leading to p53 stabilization (reviewed in [1,4,5]).
Survival signals signiﬁcantly inﬂuence both basal p53 levels
and the ability to induce p53 in response to DNA damage-
inducing agents [6–11]. These signals are mediated through the
PI3-kinase (phosphatidylinositol 3-kinase) pathway leading to
the activation of protein kinase B (also known as AKT
[hereafter AKT]; reviewed in [12,13]). AKT, in turn, has been
reported to phosphorylate MDM2 at two sites, serines 166 and
186 [8,11]. Recent studies, however, have raised uncertainty* Corresponding author. Fax: +44-1382-669993.
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forts to clarify identiﬁcation.
In exploring the regulatory mechanisms that govern MDM2
action, we have screened cell extracts for protein kinase ac-
tivities which phosphorylate sites within amino acids 108–200
of human MDM2. In normally growing, unstressed cells we
detect several activities which phosphorylate this region and
conﬁrm that one of these protein kinases is, indeed, AKT.
Strikingly, we ﬁnd that Ser-188 is the major site in human
MDM2 that is phosphorylated by AKT in vitro and is a novel
site of AKT-mediated phosphorylation in vivo.2. Materials and methods
2.1. Specialized reagents
Puriﬁed, recombinant enzymes (activated where appropriate) were
obtained as follows: AKT1/PKBa, p90RSK1 (MAPKAPK-1a), and
p70S6K-1 (ribosomal protein S6 kinase-1) were from Prof. D. Alessi,
MRC Protein Phosphorylation Unit, University of Dundee; p70S6K-2
(ribosomal protein S6 kinase-2) was a gift from Dr. Ivan Gout (Lud-
wig Institute, University College, London); and Chk1 was a gift from
Dr. Jim Hutchins (Biomedical Research Centre, Dundee).
2.2. Construction of plasmids expressing GST-MDM2 fusion proteins
Expression and puriﬁcation of a series of fusion proteins comprising
glutathione S-transferase (GST) linked to the N-termini of full length
MDM2 or overlapping domains of the MDM2 protein (termed MP1
[MDM2 aa 1–110], MP2 [108–200], MP3 [196–282] and MP4 [276–
491]) have been described elsewhere [15,16].
2.3. Mutagenesis and oligonucleotides
Site-directed mutagenesis was performed using the Stratagene
Quick-Change system according to the manufacturer’s protocol. Fol-
lowing mutagenesis, the DNAs were sequenced to ensure that only the
desired mutations were present.
2.4. Antibodies
The following antibodies were used: MDM2 (D12 and SMP-14,
both from Santa Cruz Biotechnology Inc.); AKT (polyclonal antibody
from Prof. D. Alessi, University of Dundee), Ran (from Dr. B.
McStay, University of Dundee), and Myc 9E10 (CRUK).
2.5. Generation and puriﬁcation of phospho-speciﬁc antibodies
Rabbit polyclonal phospho-speciﬁc antibodies were raised against
the phosphopeptides: SRRRAIS(phos)ETEEN (phospho-serine 166)
and KSDS(phos)ISLSFDES (phospho-serine 188), coupled to keyhole
limpet hemocyanin, and a mouse monoclonal antibody was raised
against the phosphopeptide: QRKRHKS(phos)DSIS (phospho-serine
186), coupled to keyhole limpet hemocyanin. Antibodies were aﬃnity-
puriﬁed on sepharose 4B resin to which the appropriate phosphorylatedblished by Elsevier B.V. All rights reserved.
Fig. 1. Cell extracts contain protein kinase activities that phosphorylate the region of human MDM2 comprising amino acids 108–200. (a) MCF-7
cell extracts were fractionated on a HiTrap Q column and eluted with a gradient of NaCl. Kinase activities were measured using the MP2 mini-
protein. (b) Western blot showing the presence of the AKT in the fractions. (c) MDM2 kinase activity following immuno-depletion of AKT with
anti-AKT and anti-Ran (control) antibodies. (d) Schematic representation showing the MDM2 protein and the four GST-MDM2 fusion proteins
(MP1-4) used as substrates. (e) Phosphorylation of equal amounts of each of the four mini-proteins, MP1-MP4, by AKT. The positions of the mini-
proteins are indicated.
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column containing the unphosphorylated peptide to remove any an-
tibodies that did not recognize the phosphorylated epitope.
2.6. Cell lines and transfection
MCF-7 (breast carcinoma) cells, U2OS (osteosarcoma) and OSA
(SJSA; osteosarcoma) cells, all expressing wild type p53, were routinely
grown in Dulbecco’s modiﬁed Eagle’s medium containing 10% (v/v)
bovine fetal serum. Cells were transfected with plasmid DNAs using
Lipofectamine (Life Technologies).
2.7. Immunoprecipitation and Western blotting
Immunoprecipitation and Western blotting were carried out using
standard procedures as described previously [17]. For the detection ofphosphorylated species of MDM2, the phospho-speciﬁc antibodies
described above were used at a concentration that was optimized
empirically and in the presence of unphosphorylated peptide, again at
an empirically optimized concentration, to minimize any cross reac-
tivity with the unphosphorylated protein. Blocking and subsequent
procedures were carried out in Tris-buﬀered saline containing 5% (w/v)
bovine serum albumin and 0.1% (v/v) Tween 20.
2.8. Preparation of cell extracts for protein kinase assays and ion
exchange chromatography
Cell extracts were prepared and ion exchange chromatography car-
ried out as described previously [18] with the exception that a HiTrap
Q column (Amersham Pharmacia Biotech) was used. Column fractions
and the unbound ‘‘ﬂow-through’’ material were screened for protein
272 D. Milne et al. / FEBS Letters 577 (2004) 270–276kinase activity using the MP2 proteins (GST fused to MDM2 amino
acids 108–200) as substrates.
2.9. Protein kinase assays
MDM2 kinase assays were performed in 50 mM Tris, pH 7.5, 10
mM MgCl2 and 20 lM [c-32P]ATP (Amersham Pharmacia Biotech, at
a speciﬁc activity of 12.5 Ci/mmol) in a volume of 20 ll. Assays were
initiated by the addition of protein kinase (generally 0.5–1 unit [nmol/
min] of activity) and incubated at 30 C for 30 min. Reactions were
terminated by adding SDS sample buﬀer and heating at 100 C for 2
min. Phosphorylated proteins were detected following SDS–PAGE
and autoradiography. Alternatively, a non-radioactive assay was used
in which the ATP concentration was 100 lM and the phosphorylated
proteins were detected by Western blotting using phospho-speciﬁc
antibodies.
2.10. Tryptic phosphopeptide mapping
Two-dimensional thin layer phosphopeptide analysis of MDM2 was
carried out using essentially the same procedure as described for p53
[19] with the exception that the solvent used for the chromatographic
separation comprised isobutyric acid (62.5%, v/v), n-butanol (1.9%, v/
v), pyridine (4.8%, v/v) and glacial acetic acid (2.9%, v/v) in deionized
water.Fig. 2. AKT phosphorylates Ser-166 and Ser-188 in MDM2. (a)
Phosphorylation of GST-MDM2 fusion protein MP2, or a series of
Ser-Ala substitution mutants, in vitro by recombinant AKT. Ap-
proximately equal amounts of substrate proteins were used in each
assay (lower panel). (b) Kinase activity of HiTrap Q column fractions
towards WT GST-MDM2 (MP2) and a S188A mutant. (c) Western
blotting of in vitro-phosphorylated MP2, or alanine substitution mu-
tants, using phospho-speciﬁc antibodies. Each of the small left hand
panels shows positive (MP2 phosphorylated by the Chk1 kinase) and
negative (unphosphorylated MP2) controls for each phospho-speciﬁc
antibody. Approximately equal amounts of substrate proteins were
used in each assay (lower panel).3. Results and discussion
3.1. MDM2 is phosphorylated in vitro by the protein kinase
AKT (PKB)
Ion exchange chromatography on a HiTrap Q column re-
vealed two sharp peaks of protein kinase activity that phos-
phorylated the MP2 protein (GST linked to amino acids 108–
200 of MDM2; Fig. 1(a)). A third MP2 kinase activity(ies) was
present in the ﬂow-through fraction and did not arise from
over-loading the column (data not shown). Western blotting
analysis of the fractions with an anti-AKT polyclonal antibody
indicated that AKT co-elutes with the second of the two
MDM2 kinase activities (Fig. 1(b)). Immuno-depletion of
AKT from the peak fraction (fraction 17) led to loss of the
MDM2 protein kinase activity, while an irrelevant antibody
(anti-Ran) failed to deplete the MDM2 kinase (Fig. 1(c)).
When phosphorylation reactions were carried out in the
presence of recombinant, activated AKT using a series of
MDM2 mini-proteins as substrates (Fig. 1(d)), the MP2 pro-
tein became highly phosphorylated (Fig. 1(e)). In contrast,
neither the MP1 nor MP4 proteins were phosphorylated. A
low level of phosphorylation was observed with the MP3
protein, but this was signiﬁcantly less than that observed with
MP2 (Fig. 1(e)). GST alone was not a substrate for re-
combinant AKT (data not shown). These data are consistent
with the idea that MDM2 is a target for phosphorylation by
AKT in vitro and that the site(s) or phosphorylation lie be-
tween amino acids 108 and 200.
3.2. MDM2 is phosphorylated by AKT in vitro at Ser-166 and
Ser-188, a novel target residue for AKT
To identify the site(s) of AKT phosphorylation in MDM2,
in vitro phosphorylation reactions were carried out in the
presence of activated, recombinant AKT using the MP2 mini-
protein, or a series of MP2 derivatives encompassing serine to
alanine substitutions at potential sites of phosphorylation, as
substrates. While wild type [WT] MP2, S157A, S166A and
S186A mutants, and a S166A/S186A double mutant were all
phosphorylated by AKT to a similar extent, phosphorylation
of an S188A mutant was signiﬁcantly reduced, but not com-
pletely abolished (Fig. 2(a)). Similarly, when the WT or S188AMP2 proteins were phosphorylated in the presence of the peak
HiTrap Q fractions containing AKT, phosphorylation of the
S188A mutant was greatly reduced (Fig. 2(b)). Taken together,
these data suggest that Ser-188 is the principal, but not the
sole, target of AKT in vitro. To explore further the identity of
the sites phosphorylated by AKT, the phosphorylation site-
mutant proteins used in panel (a) were phosphorylated by re-
combinant Akt in vitro and analyzed by Western blotting us-
ing phospho-speciﬁc antibodies recognizing phosphoserines
166, 186 and 188, respectively. The data (Fig. 2(c)) conﬁrmed
that Ser-188 was phosphorylated by AKT and indicated that
Ser-166 could also be modiﬁed. Phosphorylation of ser186 was
not detected using this approach (Fig. 2(c)). As an additional
means of conﬁrming the sites of phosphorylation, the MP2
protein was phosphorylated by AKT over a 2 h time period.
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and analyzed by mass spectrometry and solid phase sequenc-
ing. This approach conﬁrmed that Ser-166 and Ser188 were
targets of AKT (data not shown).
To eliminate the possibility that Ser-188 was a cryptic
phosphorylation site revealed in the MP2 protein, GST-full
length MDM2 was phosphorylated by recombinant AKT and
analyzed by phosphopeptide mapping. The phosphopeptide
maps obtained from full length MDM2 and MP2 were iden-
tical (Fig. 3(a) and (b)). Moreover, when the phosphopeptides
from each reaction were mixed prior to loading on the thin
layer plate, the phosphopeptides co-migrated (panel c). When
the S188A mutation was introduced into the full length pro-
tein, the major phosphopeptide disappeared (panel d). These
data conﬁrm that, in the context of full length MDM2, Ser-188
is the major site of phosphorylation by AKT in vitro.
3.3. Ser-166 and Ser-188 are phosphorylated in vitro and in
cultured cells in response to serum stimulation
To provide further support that the protein kinase detected
in cell extracts was indeed AKT, the PI3-kinase pathway was
stimulated in serum-starved cells by the re-addition of serum.
Protein kinase assays, in which phosphorylation of the MP2Fig. 3. AKT phosphorylates full length MDM2. Tryptic phosphopeptide ma
MDM2 in which Ser-188 is substituted by alanine (FL 188, panel (d)), phosp
phosphopeptides from the MP2 and the full length MDM2 phosphorylation
MP2 mix, panel (c)). The arrow in panel (d) indicates the absence of the majoprotein was measured by the incorporation of radioactive
phosphate from [c-32P]ATP, showed that MP2 kinase activity
was rapidly stimulated following the addition of serum to the
cells (Fig. 4(a)). When the S188A mutant was used as substrate
in this assay, stimulation of MP2 kinase activity was still evi-
dent but the level of phosphorylation was much less, indicating
that Ser-188 was a target of the stimulated kinase. Signiﬁ-
cantly, a low level of Ser-188 kinase activity was already
present in the unstimulated cell extracts, suggesting that an
additional Ser-188 kinase activity was present.
To determine whether Ser-166 kinase activity was also
stimulated, protein kinase assays were carried out in the
presence of unlabeled ATP followed by Western blotting
using the Ser-166(P) phospho-speciﬁc antibody as probe.
Using this approach, Ser-166 kinase activity was also ob-
served within 30 min following the re-addition of serum
(Fig. 4(b)). Signiﬁcantly, and consistent with the data in
panel (a) obtained from using the S188A substrate, no Ser-
166 activity could be detected in the unstimulated cells using
this approach. Taken together, these data are consistent with
the idea that growth/survival factor stimulation of the PI3-
kinase pathways leads to AKT-dependent phosphorylation
of MDM2.pping of MP2 (a), GST-tagged MDM2 (FL WT (b)), and GST-tagged
horylated in vitro by AKT. In panel (c), equal amounts of radioactive
reactions were mixed prior to loading onto the thin layer plate (FLwt/
r phosphopeptide in the map obtained from the FL188 mutant protein.
274 D. Milne et al. / FEBS Letters 577 (2004) 270–276To determine whether Ser-166 was phosphorylated in an
AKT-dependent manner in cultured cells, phosphorylation of
endogenous MDM2 was determined following Western blot-
ting of stimulated cell extracts using the Ser-166(P) phospho-
speciﬁc antibody. The data indicate that MDM2 underwent
serum-dependent phosphorylation of Ser-166 (Fig. 4(c)) with
kinetics that match the in vitro measurements of Ser-166
protein kinase activity in panel (Fig. 4(b)). When the cells were
pretreated with LY294002, a speciﬁc inhibitor of PI3-kinase
(and consequently of AKT activation), the serum-dependent
phosphorylation of Ser-166 in MDM2 was abolished, sug-
gesting that phosphorylation of MDM2 occurs through the
PI3-kinase pathway. A similar set of data were obtained using
MCF-7 cells (data not shown).
PI3-kinase also lies upstream of p70S6K1, p70S6K2 and
p90RSK. However, none of these kinases was able to
phosphorylate serine 188 in vitro and only p90RSK phos-
phorylates Ser-166 (data not shown). Additionally, however,Fig. 4. MDM2 is phosphorylated at Ser-166 in response to serum stimulation.
24 h. Cells deprived of serum were stimulated in the presence of 20% FBS
phorylation reactions were carried out in vitro on GST-MDM2. (a) Detect
donor. (b) Western blotting was performed using the anti-phospho-serine 166
response to serum and in the presence or absence of the PI3-kinase inhibito
antibodies SMP14 and D12. Immunoprecipitated proteins were Western blotp90RSK requires the extracellular ligand-activated kinase
(ERK) pathway for activity [20]. Treatment of MCF-7 cells
with U0126, an inhibitor of MEK (the protein kinase which
activates ERK), did not block MDM2 phosphorylation of
Ser-166 (data not shown). Taken together, the data are
consistent with the idea that AKT is the serum-stimulated
MDM2 Ser-166 kinase and conﬁrm previously published
ﬁndings [7–9,11,14].
To determine initially whether Ser-188 was a physiological
site of phosphorylation, WT MDM2 and an S188A mutant
were expressed in MCF-7 cells, following which the cells were
pulse-labeled with 32P-orthophosphate. Two-dimensional
tryptic phosphopeptide mapping (Fig. 5(a)) showed that a
major phosphopeptide present in WT MDM2 (indicated by a
black arrow) was signiﬁcantly depleted in the S188A mutant
protein. In vitro analysis established that this peptide con-
tained Ser-188 [data not shown]. These data support the idea
that Ser-188 is phosphorylated physiologically. The residualU2OS cells were maintained in 10% FBS or in the absence of serum for
for up to 8 h. (a, b) Cell extracts were prepared and MDM2 phos-
ion by autoradiography when [c-32P]ATP was used as the phosphate
, or anti-GST antibodies. (c) Phosphorylation of endogenous MDM2 in
r, LY294002. MDM2 was immunoprecipitated using the monoclonal
ted for the presence of phospho-serine 166 and MDM2 (SMP14/D12).
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more of the remaining four serine residues within this peptide.
Attempts to detect serum-induced Ser-188 phosphorylation
of MDM2 in U2OS or MCF-7 cells using the Ser-188(P)
phospho-speciﬁc antibody were limited by the low levels of
MDM2 in these cells and low sensitivity of the antibody. To
overcome this diﬃculty, the experiments were carried out using
SJSA cells which express high levels of endogenous MDM2.
As with the U2OS cells, re-addition of serum to serum-starved
SJSA cells led to stimulation of Ser-188 kinase activity
(Fig. 5(b)). Activation of this kinase was abolished when the
cells had been pretreated with LY294002. As with the U2OS
cells, there appeared to be a basal level of Ser-188 kinase ac-
tivity in the unstimulated cells, suggesting that either the Ser-
188 antibody could detect a low level of unphosphorylatedFig. 5. MDM2 is phosphorylated physiologically at Ser-188. (a) Tryptic phosp
Myc-tagged WT or S188A MDM2 and pulse-labeled with 32P-orthophosp
phosphopeptides. The sequence shown at the base of the plates represents a
serine 188. The vertical arrows indicate the sites of trypsin digestion. (b) SJSA
up to 2 h. Cell extracts were prepared and MDM2 phosphorylation reacti
performed using the anti-phospho-serine 188, or anti-GST antibody. (c) Pho
presence or absence of the PI3-kinase inhibitor, LY294002. Immunoprecipita
serine 188 and MDM2 (SMP14/D12).substrate or, more likely, that another Ser-188 kinase was
present in the extracts. Stimulation of Ser-166 kinase activity
was also detected in SJSA cells with identical kinetics to the
induction of the S188 activity (data not shown).
Western blotting analysis of the endogenous MDM2, using
the Ser-188(P) phospho-speciﬁc antibody, indicated that Ser-
188 phosphorylation was indeed serum-dependent and could
be inhibited by pretreating the cells with LY294002 (Fig. 5(c)).
Again, the kinetics of Ser-188 phosphorylation reﬂected acti-
vation of the protein kinase (compare with panel b). These
data support the idea that Ser-188 is phosphorylated physio-
logically by AKT. Additionally, the data suggest a low level of
serum-independent Ser-188 phosphorylation consistent with
the conclusions reached from the in vitro kinase assays (Figs.
4(a) and 5(b)).hopeptide mapping of MCF-7 cells transfected with plasmids encoding
hate. Arrowheads mark the origins. Black arrows show the Ser-188
mino acids 185-204 of MDM2 and indicates the position of phospho-
cells deprived of serum were stimulated in the presence of 20% FBS for
ons were carried out in vitro on GST-MDM2. Western blotting was
sphorylation of endogenous MDM2 in response to serum and in the
ted MDM2 proteins were Western blotted for the presence of phospho-
276 D. Milne et al. / FEBS Letters 577 (2004) 270–2763.4. MDM2-Ser-188 as a novel target for phosphorylation by
AKT
While there is general agreement that AKT regulates
MDM2 physiologically [6–11,14], several groups have not been
able to detect AKT-mediated phosphorylation of Ser-186
[6,7,14], one of the sites originally reported as an AKT target
[8,11]. In the present study, we conﬁrm that Ser-186 is not a
major target of AKT in vitro but verify that Ser-166 is an AKT
target both in vitro and in vivo. We have not been able to
detect AKT-mediated Ser-186 phosphorylation of endogenous
MDM2 using the Ser-186(p) phospho-speciﬁc antibody (data
not shown). In contrast, we have identiﬁed a novel AKT
phosphorylation site, Ser-188, which is the major site modiﬁed
by AKT in vitro (Figs. 2 and 3). Like Ser-166, Ser-188 kinase
activity is induced by serum stimulation (Figs. 4(a) and 5(b)).
Moreover, serum-induced phosphorylation of Ser-188 in en-
dogenous MDM2 occurs in a LY294002-sensitive manner,
consistent with this residue being a cellular target of AKT
(Fig. 5(c)).
While the present manuscript was in preparation, Feng et al.
[14] published a study indicating that Ser-188 of MDM2 is a
major target of AKT in vitro and in vivo. The data presented
in the present study are therefore supportive of the conclusions
of Feng et al. [14] and highlight the physiological relevance of
Ser-188 as a novel AKT target.
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